Table 1. Patient and tumor characteristics.
| ID | Age | M/F | Survival (weeks) from resection | Survival (weeks) from diagnosis | Pathology | Prior Treament |
| GBM.1 | 74 | F | 4 | 4 | GBM | – |
| GBM.2 | 66 | F | (6) | (35) | GBM | RT |
| GBM.3 | 71 | F | 12 | 34 | GBM | RT |
| GBM.4 | 70 | F | 46 | 46 | GBM | – |
| GBM.5 | 39 | M | 32 | 45 | GBM | RT |
| GBM.6 | 67 | F | 150 | 150 | GBM | – |
| GBM.7 | 42 | M | 138 | 138 | GBM | RT |
| GBM.8 | 56 | M | 27 | 60 | GBM | RT + temozolomide |
| GBM.9 | 40 | M | 14 | 206 | Secondary GBM | PCV |
| GBM.10 | 52 | M | 35 | 35 | GBM | – |
| GBM.11 | 71 | M | 32 | 32 | GBM | – |
| GBM.12 | 53 | F | 5 | 44 | GBM | RT + temozolomide |
| GBM.13 | 47 | M | 35 | 38 | GBM, oligoastrocytoma features | – |
| GBM.14 | 59 | M | 21 | 47 | GBM | RT + temozolomide |
| GNT.15 | 68 | M | 51 | 69 | High grade glioneuronal tumor | RT |
| GBM.16 | 38 | M | 15 | 94 | GBM | RT |
| GBM.17 | 60 | F | 49 | 49 | GBM | – |
| GBM.18 | 32 | F | (3) | (84) | GBM | RT, high dose thiotepa |
| GBM.19 | 49 | M | 85 | 85 | GBM | – |
| GBM.20 | 71 | M | 212 + | 212 + | GBM | – |
| AO.21 | 64 | F | (218) | (218) | anaplastic oligodendroglioma | – |
| ODG.22 | 52 | F | (6) | (475) | oligodendroglioma | – |
| AA.23 | 46 | F | (76) | (544) | anaplastic astrocytoma | high-dose thiotepa |
| AO.24 | 45 | M | 194 + | 198 + | anaplastic oligodendroglioma | – |
| ODG.25 | 42 | F | 153 + | 153 + | oligodendroglioma | – |
| AA.26 | 47 | F | 35 | 254 | anaplastic astrocytoma | RT |
| GBM.27 | 74 | M | 7 | 55 | GBM | RT + temozolomide |
Demographic and pathologic description for 27 study patients. Survival is shown from time of resection of study tumor: “+” = still alive and parentheses mark patients lost to follow-up. For recurrent tumors, prior treatment and survival from initial diagnosis.